1:00 - 1:05 PM: Welcome
1:05 - 1:55 PM: What the November 2022 Election Outcomes Will Mean for Patients and Health Care
The national mid-term elections, along with state-level executive and legislative races, received a tremendous amount of attention and will have far-reaching implications for years to come. Policy pundits will assess federal and Michigan election results and their potential impact on how health policy and priorities will advance beginning in 2023 — and how patient advocacy groups can prepare for what’s next.
1:55 - 2:00 PM: Break
2:00 - 2:55 PM: Biomarker Screening: The Future of Precision Medicine and Improving Health Access
Biomarkers are biological characteristics helping increasingly in the prediction, cause, diagnosis, progression, and regression of disease, and as a consequence of therapeutic treatments or medical interventions. Scientific and medical experts will discuss the science and application of biomarker testing, including multi-cancer screening, and how biomarkers have advanced treatment for many patients and the critical need to make testing more accessible for Michiganders.
2:55 - 3:00 PM: Break
3:00 - 3:55 PM: Patients Engaging: Empowering Your Voice
Patients are essential partners in developing measurable value in healthcare. Their voices should be heard by all stakeholders in the healthcare continuum – innovators, manufacturers, providers, payers, regulators and policymakers – from scientific discovery to care delivery and management. The key to patient empowerment is to be knowledgeable and actively engaged on matters related to healthcare access. Key opinion leaders will talk about how to ensure patient preferences in decision-making while achieving improved outcomes and better experiences.
3:55 - 4:00 PM: Break
4:00 - 4:30 PM: Policy Priorities: Setting a Legislative Agenda for 2023
A new legislative season begins in January 2023 and what will be foremost on patient minds when it comes to policy priorities? Results from a pre-Forum survey of patient groups will be presented and discussed. A framework for a policy agenda will be developed that will serve as a common rallying point that patient groups and industry can partner around.